Abstracts of the 5(th) Cachexia Conference, Barcelona, Spain, December 5-8, 2009.

J Cachexia Sarcopenia Muscle · 2010 · PMC3060650 · PMID 22477519

Europe PMC DOI

hedged sentences

0.0630

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

showed a trendp = 0.063so close (0.05 < p ≤ 0.1)

Gabarapl1 showed a trend towards elevation ( p = 0.063) with WS patients showing the greatest fold change (1.7) compared with controls (1.1) or WL (1.5) patients.

also in 53,322 other papers

a strong trendp = 0.064so close (0.05 < p ≤ 0.1)

Low-dose MT-102 displayed a strong trend ( p = 0.064) (see Table).

also in 5,725 other papers

a clear trendno p-value reported

In the 28-day ORX rat study, GSK420A showed a clear trend of increases in other anabolic parameters, such as lean and total body mass, lumbar spine BMD/BMC, and hematocrit.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.